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Prostate cancer is one of the most common cancers in men. Although it has
a relatively high 5-year survival rate, development of resistance to standard
androgen-deprivation therapy is a significant clinical problem. Therefore,
novel therapeutic strategies are urgently needed. The protein kinase C
(PKC) family is a putative prostate cancer drug target, but so far no PKC-
targeting drugs are available for clinical use. By contrast to the standard
approach of developing PKC inhibitors, we have developed isophthalate
derivatives as PKC agonists. In this study, we have characterized the effects
of the most potent isophthalate, 5-(hydroxymethyl)isophthalate 1a3 (HMI-
1a3), on three prostate cancer cell lines (LNCaP, DU145, and PC3) using
both 2D and 3D cell culture models. In 2D cell culture, HMI-1a3 reduced
cell viability or proliferation in all cell lines as determined by the metabolic
activity of the cells (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide assay) and thymidine incorporation. However, the mechanism of
action in LNCaP cells was different to that in DU145 or PC3 cells. In
LNCaP cells, HMI-1a3 induced a PKC-dependent activation of caspase 3/7,
indicating an apoptotic response, whereas in DU145 and PC3 cells, it
induced senescence, which was independent of PKC. This was observed as
typical senescent morphology, increased b-galactosidase activity, and upreg-
ulation of the senescence marker p21 and downregulation of E2F transcrip-
tion factor 1. Using a multicellular spheroid model, we further showed that
HMI-1a3 affects the growth of LNCaP and DU145 cells in a 3D culture,
emphasizing its potential as a lead compound for cancer drug development.
Prostate cancer is one of the most common cancer types
with estimated 161 000 new diagnoses and more than
26 000 deaths in 2017 in the United States alone [1].
Worldwide around 307 000 people died of prostate can-
cer in 2012, making it the fifth most common cause of
cancer death [2]. Although the 5-year survival rate in
prostate cancer is high, its prevalence and common
development of castration resistance, followed by
androgen-deprivation therapy, is a prominent problem
and therefore alternative therapeutic strategies are
needed.
One intensively studied target for cancer treatment is
protein kinase C (PKC) family of serine/threonine
kinases (reviewed in [3]). In mammals, 10 PKC isoforms
are divided into three groups according to their mode of
activation. Classical/conventional PKCs are activated
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by both Ca2+ and diacylglycerol (DAG), novel PKCs
require only DAG for activation, and atypical PKCs
respond to neither DAG nor Ca2+, but require other
activators (such as anionic phospholipids). In both con-
ventional and novel PKC subtypes, DAG induces acti-
vation by binding to C1-domain, which is also the
binding site of phorbol-esters, potent PKC activators.
The expression levels and activity of different PKC
isoforms have been studied in various types of patient-
derived cancer tissues and cancer cell lines, with partly
contradictory results [4,5]. Nevertheless, it has been well
established that pharmacological activation of PKC
after initiation of tumor formation leads to tumor pro-
motion [6]. This observation is based on experiments
done using phorbol 12-myristate-13-acetate (PMA),
often at high concentrations, as the PKC activator.
However, prolonged exposure to high concentrations of
PMA leads to dephosphorylation and degradation (i.e.,
downregulation) of PKC. Furthermore, since all PKC
agonists are not tumor promoters, it seems plausible
that tumor promotion is not due to PKC activation
per se, but could instead be related to PKC downregula-
tion and, thus, to the lack of PKC activity. In line with
this, a recent study analyzed PKC mutations in a large
number of biopsies from various human cancers and
found that PKC in fact plays a tumor-suppressive role
[7]. In these biopsy samples, none of the observed PKC
mutations increased PKC activity, but the cancer-asso-
ciated mutations were found to be loss-of-function
mutations. Interestingly, correcting a PKCb loss-of-
function mutation in DLD1 colon cancer cell line using
CRISPR/Cas9 technique led to decreased anchorage-
independent growth in soft agar and decreased cell via-
bility in suspension [7]. In conclusion, it seems that acti-
vation of PKC, without inducing downregulation, could
provide a good strategy for treating at least some forms
of cancer. The role of PKC (mainly PKCd) in apoptosis
of prostate cancer cells has been shown in several stud-
ies [8–12]. In some of these studies, PKC was activated
directly with PMA, but also paclitaxel-induced apopto-
sis has been shown to require PKCd [13]. Furthermore,
a loss of PKCd expression in high Gleason score pros-
tate tumors has been reported and this was associated
with resistance to paclitaxel treatment [14].
Our group has developed small molecule compounds
designed to bind to the C1-domain of PKCs to modu-
late their activity [15]. These isophthalic acid deriva-
tives modulate PKC activity without inducing
downregulation of PKC (Fig. S1). We have previously
shown that they induce a morphological change (elon-
gation) in HeLa human cervical cancer cells and inhi-
bit their proliferation [16]. In order to further explore
the potential of isophthalate derivatives in cancer drug
development, we elucidated the effects of 5-(hydroxy-
methyl)isophthalate 1a3 (HMI-1a3) in androgen-
responsive and androgen-unresponsive prostate cancer
cell lines, namely LNCaP, DU145, and PC3.
Materials and methods
Chemicals
All chemicals used in this study were commercially available,
except for the isophthalate derivative HMI-1a3 (bis(3-tri-
fluoromethylbenzyl) 5-(hydroxymethyl)isophthalate) and
NI-15e (bis(3-trifluoromethylbenzyl) 5-nitroisophthalate),
which were synthesized at the Division of Pharmaceutical
Chemistry and Technology, Faculty of Pharmacy, University
of Helsinki, as described previously (Boije af Genn€as et al.
[15]). The identity of the compounds was verified with a Bru-
ker Ascend 400 MHz-Avance III HD NMR spectrometer
(Bruker Corporation, Billerica, MA, USA), and the purity of
each batch was at least 95% as confirmed by LC-MS analy-
ses with a Waters Acquity UPLC system (Waters, Milford,
MA, USA) equipped with an Acquity UPLC BEH C18
column (1.7 lm, 50 9 2.1 mm, Waters, Dublin, Ireland), an
Acquity PDA detector and a Waters Synapt G2 HDMS mass
spectrometer (Waters, Milford, MA, USA) via an ESI ion
source in positive mode. Phorbol 12-myristate 13-acetate
(PMA), bryostatin-1, doxorubicin, pan-caspase inhibitor Q-
VD-OPH, and the pan-PKC inhibitor G€o6983 were from
Sigma-Aldrich (Steinheim, Germany). Staurosporine was
from Tocris Bioscience (Bristol, UK).
Cell culture
LNCaP, DU145, and PC3 cells were from ATCC (Manassas,
VA, USA) (HTB-81; CRL-1740 and CRL-1435) and were
authenticated using microsatellite markers (Promega Gene-
Print 10 System, Promega, Madison WI, USA) at the Insti-
tute for Molecular Medicine Finland FIMM Technology
Centre (University of Helsinki, Finland) to confirm their
identity. LNCaP and DU145 were cultured in RPMI1640
medium (Cat #1060120, MP Biomedicals, Santa Ana, CA,
USA), PC3 cells in Ham’s F12K (Kaighn’s modification, Cat
#21127022; Gibco, Thermo Fisher Scientific, Waltham, MA,
USA) medium, and HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium (D-7777; SIGMA) all of which
were supplemented with 10% fetal bovine serum,
100 UmL1 penicillin, and 100 lgmL1 streptomycin (all
from Gibco). Cell cultures were maintained in a humidified
incubator with 5% CO2 at 37 °C. All experiments were done
in the above-described cell culture media.
Cell viability assays
Cell viability was measured using mitochondrial oxidore-
ductase activity assay [3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyl-tetrazolium bromide (MTT)], and lactate dehydro-
genase (LDH) test was used to measure the amount of
LDH released from cells with compromised cell membrane
integrity. The cells were plated on 96-well plates (8000–
10 000 cells per well, in serum-supplemented media) and
exposed to the compounds for 24 h, after which LDH
assay was carried out using 50 lL samples of cell culture
media and MTT assay with the cells. For LDH assay,
50 lL of LDH substrate solution (1.3 mM b-nicotinamide
adenine dinucleotide, 660 lM iodonitrotetrazolium, 54 mM
L(+)-lactic acid, 280 lM phenazine methosulphate (all from
Sigma-Aldrich) in 0.2 M Tris/HCl, pH 8.2) was added to
the media samples. After a 30-min incubation at room tem-
perature (RT), the reaction was stopped by adding 50 lL
of 1 M acetic acid and the absorbance was measured at
490 nm. Background absorbance was measured from the
wells without cells. Untreated cells were used as controls
for spontaneous LDH release, and maximal LDH release
was determined from cells lysed with 0.9% Triton X-100
prior to taking media samples. For the MTT assay, MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide, from Sigma-Aldrich) solution was added to the cells
at 0.5 mgmL1. The cells were then incubated in cell cul-
ture conditions for 2 h, after which cell culture media was
aspirated and replaced with 200 lL DMSO. The absor-
bance was then measured at 550 nm with absorbance at
650 nm subtracted as background.
Thymidine incorporation assay
The cells were plated on 6-well plates (500 000 LNCaP cells
per well and 250 000–300 000 PC3 or DU145 cells per well)
and 48 (LNCaP) or 24 h after plating exposed to the test
compounds for 24 h. For the last 6 h of treatment,
[methyl-3H] thymidine (PerkinElmer, Turku, Finland) was
added in the incubation medium at 1 lCimL1. After
incubation, the cells were washed with ice-cold PBS and
free unbound thymidine was precipitated with 5% trichlor-
oacetic acid and discarded. Finally, the cells were lysed
with 0.1 M NaOH and the lysates collected to scintillation
vials. Optiphase HiSafe scintillation cocktail (PerkinElmer)
was added, and the counts were measured with Wallac
scintillation counter (PerkinElmer).
Apoptosis assay
Activation of caspase 3/7 was used to determine whether
apoptosis was induced in the cells. Briefly, cells were grown
on white-walled clear bottom 96-well plates (PerkinElmer)
and treated with test compounds as described above for the
MTT assay. After a 24-h treatment, caspase 3/7 activation
was determined with Caspase-Glo 3/7 Assay kit (Promega)
according to the manufacturer instructions and the lumi-
nescence was quantified using Victor2 microplate reader
(PerkinElmer).
Beta-galactosidase staining and activity
measurements
For the b-galactosidase staining, the cells were seeded on
24-well plates at 20 000–30 000 cells per well 24 h prior to
treatment. The cells were then treated with test compounds
for 72 h, fixed, and stained with Senescence b-galactosidase
Staining kit (#9860, Cell Signaling Technology, Danvers,
MA, USA) according to the manufacturer’s instructions.
Briefly, the cells were rinsed once with PBS, fixed with solu-
tion provided in the kit for 15 min at RT, and rinsed again
two times with PBS. Staining solution was then added to
the cells, and the well plate was sealed and incubated for
overnight at 37 °C in normal atmosphere. The cells were
examined and imaged with Canon EOS 600D camera
(Canon, Tokyo, Japan) on Olympus CKX41 inverted
microscope (Olympus, Tokyo, Japan) on the following day.
b-Galactosidase activity was measured utilizing 96-well
Cellular Senescence Assay kit (CBA-231; Cell Biolabs, San
Diego, CA, USA). For this assay, cells were seeded on a
96-well plate at 2000 cells per well, let to attach overnight,
and treated with the compounds for 72 h. After treatment,
the cells were rinsed with PBS and lysed. Lysates were cen-
trifuged and the supernatants collected and incubated with
fluorescent substrate for 2 h at 37 °C, protected from light.
The reaction was then stopped and the fluorescence (Ex
360 nm/Em 465 nm) measured with Victor2 microplate
reader (PerkinElmer).
Western blotting
The cells were grown on 6-well plates and exposed to the
compounds for 24 or 48 h after which they were washed with
ice-cold PBS and lysed on ice with lysis buffer (1 mM EDTA,
150 mM NaCl, 0.25% NP-40, 1% Triton X-100, 10 mM Tris/
HCl, pH 6.8) supplemented with protease and phosphatase
inhibitors (Complete and PHOStop, respectively; Roche,
Mannheim, Germany). Lysates were centrifuged (13 000 g,
4 min, 4 °C) and the supernatants collected. Equal amounts
of protein (10 lg) were subjected to reducing SDS/PAGE
and transferred to poly(vinylidene difluoride) membrane.
The membranes were blocked either with 5% milk in 0.1%
Tween 20 in Tris-buffered saline (TBST) or 5% BSA in
TBST for 1 h at RT, after which they were incubated over-
night at 4 °C in a shaker with primary antibodies (all from
Cell Signaling Technology, except anti-GAPDH) against
E2F1 (Cat #3742, 1 : 2000), p21 Waf1/Cip1 (Cat#2946,
1 : 1000), cleaved PARP (#9541, 1 : 1000), and GAPDH
(sc47724, 1 : 2000, Santa Cruz Biotechnology, Dallas, TX,
USA) in blocking buffer. For determining the PKC protein
levels in HeLa cells, all primary antibodies were from Santa
Cruz Biotechnology PKCa (#8393), PKCbI (#8049), PKCd
(#937) and were used as 1 : 1000 dilution. The experiments
were repeated 3 times with 2 parallels. On the following day,
the membranes were washed with TBST and incubated with
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blocking buffer containing HRP-linked secondary antibody
(goat anti-rabbit, #170-6515; Bio-Rad, CA, USA or anti-
mouse IgG #7076S; Cell Signaling Technology) for 1 h at
RT. Secondary antibodies were detected with chemilumines-
cent substrate (SuperSignal West Pico, #34080; Thermo
Fisher) utilizing LAS 3000 Imaging System (Fujifilm, Tokyo,
Japan). Quantification was carried out by measuring the
optical densities of the immunoreactive bands using IMAGEJ
software (https://imagej.net/Downloads). The optical densi-
ties were always first normalized to GAPDH from the same
sample and then to the corresponding control (cells treated
with the vehicle only) on the same membrane.
Total Akt and phosphorylated Akt immunoassays
Total Akt and phosphorylated Akt (Ser 473) levels were
determined using AlphaLISA Surefire Ultra kits (Cat #
ALSU-PAKT-B500 and ALSU-TAKT-B500; PerkinElmer).
Briefly, LNCaP cells were seeded on 96-well plates
(10 000 cells per well) and exposed to compounds 48 h
after plating. Some of the cells were first pre-incubated with
the PKC inhibitor G€o6983 for 10 min and then exposed to
compounds for 20 min. After treatment cells were washed
briefly with PBS and then lysed with 50 lL per well of lysis
buffer from the kit on a shaker for 10 min. After that
10 lL of lysates was transferred onto a 384 plate (Alphap-
late; PerkinElmer) and 5 lL of acceptor bead mix was
added in each well. After a 1-h incubation at RT, 5 lL of
donor bead mix was added, and the plate incubated for
further 1 h (RT) and then measured with EnSpire Multi-
mode Plate Reader (Ex 680 nm, Em 615 nm; PerkinElmer).
3D cell culture and live/dead assay
LNCaP or DU145 cell was plated at 5000 cells per well on U-
bottom 96-well plate coated with agarose. The spheroids were
allowed to form for 72 h, after which the compounds were
added. After a 72-h compound exposure, live/dead staining
(Thermo Fisher) was performed according to the manufac-
turer’s instructions. Briefly, Hoechst 33342, Calcein AM, and
Ethidium Dimer-1 solutions were diluted and mixed in PBS
and added to the spheroids in final concentrations of 10, 2,
and 4 lM, respectively. The spheroids were then incubated in
humidified incubator at 37 °C for 30 min, protected from
light. Spheroids were imaged with Hamamatsu Orca-Flash4.0
V2 sCMOS camera on a Leica DMi8 inverted fluorescent
microscope with 20X objective and the following filter sets:
Ethidium Dimer-1 (live cells) ex 494 nm/em 517 nm; Calcein
AM (dead cells) ex 528/em 617 nm; and Hoechst (nuclei) ex
350 nm/em 460 nm (Leica, Wetzlar, Germany).
Statistics
All statistical analyses and determination of relative EC50-
values from MTT data were done with GRAPHPAD PRISM
version 5.02 for Windows (GraphPad Software, La Jolla, CA,
USA, www.graphpad.com). Unpaired t-test or one-way
ANOVA followed by Dunnett’s test was used for all compar-
isons as indicated in the figure legends. Control refers to expo-
sure to vehicle (0.1% DMSO), and N refers to the number of
independent experiments. Each experiment was repeated at
least three times with two or more parallel samples, depending
on the experiment, and is indicated in the figure legend.
Results
HMI-1a3 reduces the viability of prostate cancer
cell lines in a dose-dependent manner
The viability of LNCaP, DU145, and PC3 cells
decreased dose dependently upon treatment with
HMI-1a3 as determined by the MTT assay (Fig. 1A).
The EC50 values were as follows: LNCaP 1.06 lM,
DU145 0.21 lM, and PC3 1.08 lM. The maximal effect
with the highest concentrations was a reduction in via-
bility to around 40% (LNCaP), 60% (DU145), and
55% (PC3). HMI-1a3 did not induce damage to the
cell membranes during the 24-h incubation in these
cells with any of the concentrations as determined by
the LDH test (data not shown).
HMI-1a3 induces proliferation arrest in all cell
lines studied
LNCaP cells show a trend toward an antiproliferative
response to HMI-1a3, when treated for 24 h, as mea-
sured with thymidine incorporation assay, but the differ-
ence compared to control was not statistically significant
with any concentration (Fig. 1B). DU145 cells exhibited
an antiproliferative response to HMI-1a3, but only with
10 lM concentration, whereas PC3 cells exhibited a
dose-dependent antiproliferative response to HMI-1a3,
already 2 lM concentration induced a statistically signif-
icant difference in proliferation when compared to con-
trol. Compound NI-15e, which is a structural analog of
HMI-1a3 that does not bind to the C1 domain, had no
effect on the proliferation of any of the cell lines. Fur-
thermore, the widely used nontumor-promoting PKC
activator bryostatin-1 did not affect cell proliferation in
any of the cell lines investigated.
LNCaP cells undergo apoptosis after 24-h
treatment with HMI 1a3
LNCaP cells have been shown to be directed to apop-
tosis upon PKC activation [11,17–19]. We therefore
tested whether the HMI-1a3 induced decrease in cell
viability observed with the MTT assay could be due to
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apoptosis in LNCaP cells. Caspases 3/7 were activated
in LNCaP cells following exposure to HMI-1a3. This
seems to be PKC-dependent, as it was blocked with
the PKC inhibitor G€o6983 (Fig. 2A). Furthermore,
the level of caspase activation in response to 20 lM
HMI-1a3 was similar to that caused by PMA at
100 nM. However, even 48-h treatment with HMI-1a3
does not induce downregulation of PKC isoforms (a,
b, and d) in HeLa cells, whereas 100 nM PMA does
(Fig. S1). The inactive isophthalate derivative NI-15e
had no effect on caspase 3/7 activity. The apoptotic
response was verified by detecting the appearance of
cleaved PARP in LNCaP cells after HMI-1a3 treat-
ment by western blotting (Fig. 2B).
Akt phosphorylation status in LNCaP cells is not
affected by HMI-1a3
Protein kinase c activation has been shown to lead to
apoptosis of LNCaP cells via dephosphorylation of
Akt [19]. In LNCaP cells, Akt is constitutively active
and phosphorylated because of nonfunctional PTEN
[20]. We therefore tested whether HMI-1a3 has any
effect on phosphorylation of Ser473 residue of Akt.
PMA at 1 lM induced a statistically significant
(P < 0.01) dephosphorylation of this site, but HMI-
1a3 only slightly decreased the phosphorylation (not
statistically significant; Fig. 2C).
HMI-1a3-induced decrease in cell viability in
DU145 and PC3 cells does not result from
apoptosis and is not mediated by PKC
Because the viability of DU145 and PC3 cells decreases
concentration dependently when cells are exposed to
HMI-1a3, we wanted to see whether this was due to
apoptosis and whether this response was PKC-mediated.
No apoptosis was detected in DU145 and PC3, as mea-
sured by activation of caspases 3/7 (Fig. 2D). In addi-
tion, the decrease in cell viability was not affected by the
PKC inhibitor G€o6983 (Fig. 2E and 2F) and thus does
not seem to be PKC-dependent.
PC3 and DU145 cells are driven to senescence
upon treatment with HMI-1a3
As the HMI-1a3-induced decrease in DU145 and PC3
cell viability did not result from apoptosis, we next
A
B
Fig. 1. Effects of HMI-1a3 on viability and proliferation of prostate cancer cell lines. (A) HMI-1a3 decreases the viability of prostate cancer
cells in a concentration-dependent manner. Cell viability was measured after 24-h incubation with HMI-1a3 utilizing MTT assay. The data are
presented as mean  SEM (N = 3). (B) The effect of HMI-1a3, NI15e, and bryostatin on proliferation of prostate cancer cell lines, as
measured after 24-h incubation with compounds using thymidine incorporation assay. The values are presented as mean + SEM (N = 3;
*P < 0.05; **P < 0.01 vs ctrl, ANOVA followed by Dunnett’s test).
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went on to characterize the mechanism. In addition to
arrest in proliferation, we observed a clear change in
the cell morphology upon exposure to HMI-1a3 in
both cell lines, the cells resembling senescent cells with
flattened appearance and granulated nuclei. We there-
fore stained the cells with a senescence marker b-galac-
tosidase, which confirmed that a proportion of the
cells were indeed senescent (Fig. 3A). Furthermore,
4 lM of HMI-1a3 induced over twofold increase in b-
galactosidase activity (P < 0.05) in both cell lines
(Fig. 3A,B). Doxorubicin, which has been shown to
induce senescence in DU145 and PC3 cells when used
in low concentration [21], did not increase b-galactosi-
dase activity under these conditions.
Finally, to confirm the senescence response, we stud-
ied the levels of p21 and E2F transcription factor 1
(E2F1). The level of p21 is increased and the level of
E2F1 decreased when cells enter senescence. There was
a trend for increased levels of p21 in PC3 cells after a
48-h treatment and in DU145 cells after a 24-h treat-
ment (Fig. 4), but the changes were not statistically
significant. Correspondingly, the levels of E2F1 tended
to decrease in DU145 cells (not statistically significant)
and decreased (P < 0.01) in PC3 cells (Fig. 4), further
confirming that the cells indeed became senescent. NI-
15e or doxorubicin had no effect on the levels of p21
or E2F1. PMA had a similar effect on p21 as HMI-
1a3, but no effect on E2F1 levels.
HMI-1a3 increases the number of dead cells in
DU145 spheroids and affects the geometry of
LNCaP cells in 3D cell culture
As the cell culture techniques evolve, it has become
more and more pronounced that especially in cancer
research the experimental models should mimic the
physiological situation as much as possible. For cancer
cells, the cell–cell contacts are of utmost importance.
A B C
D E F
Fig. 2. HMI-1a3 induces PKC-dependent apoptosis in LNCaP cells and PKC-independent nonapoptotic reduction in cell viability in DU145
and PC3 cells. (A) Caspase 3/7 activity in LNCaP cells in response to PKC modulators. (B) Apoptosis was verified in LNCaP cells by
detecting cleaved PARP with western blotting. Representative blot from three experiments is shown. (C) The proportion of phosphorylated
Akt (Ser473) in LNCaP cells in response to PKC modulators. (D) Caspase 3/7 activity in DU145 and PC3 cells in response to HMI-1a3 and
staurosporine. (E,F) The effect of PKC inhibitor G€o6983 (1 lM) on the compromised viability of DU145 (E) and PC3 cells (F) cells. Activity of
caspases 3/7 was measured with luminescent substrate and cell viability utilizing MTT assay. Akt phosphorylation was measured with
AlphaLISA immunoassay. All quantification data are presented as mean + SEM (N = 3; *P < 0.05; **P < 0.01; ***P < 0.001 vs DMSO,
ANOVA followed by Dunnett’s test).
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While in two-dimensional (2D) models, the cell–cell
contacts do not accurately reflect the situation in vivo,
3D cell culture systems recapitulate the physiological
situation more closely [22]. Therefore, we wanted to
see whether HMI-1a3 has an effect on prostate cancer
cells also in a 3D context. The LNCaP spheroids
appeared to decrease in size and became more round
and compact in a concentration-dependent manner
(Fig. 5A). The negative control compound NI-15e had
no effect on the spheroid shape, whereas PMA
induced similar rounding of spheroids as HMI-1a3.
The amount of live and dead cells was visualized using
Live/Dead staining, and while NI-15e had no effect on
the quantity of dead cells, PMA seemed to induce cell
death. In DU145 spheroids, the number of dead cells
increased with increasing HMI-1a3 concentration
(Fig. 5B). PC3 cells do not form compact spheroids in
this model and therefore were not studied.
Discussion
In search of new drug targets for prostate cancer,
PKC has been in focus for decades. The levels of dif-
ferent PKC isoforms in prostate cancer have been
studied [4] and both inhibition and activation of PKC
have been suggested as promising strategies for
treating prostate cancer [8,14,19,23,24]. The recent
comprehensive analysis of cancer-associated mutations
in PKC isoforms indicates that the role of PKCs is in
fact tumor-suppressive [7]. This explains at least par-
tially the failures in PKC-targeted cancer drug discov-
ery, as the efforts by pharmaceutical companies have
mainly been directed toward developing PKC inhibi-
tors. Of note, the only PKC-targeted drug accepted
for clinical use is ingenol mebutate, a PKC activator
used for the treatment of actinic keratosis (preliminary
stage of skin cancer) [25]. Development of activators,
which do not induce downregulation of PKC protein
levels (and thereby reduction in activity), thus seems to
be the most promising strategy for PKC-targeted can-
cer drug discovery. PKC maturation involves phospho-
rylation of several sites, for example, activation loop.
These mature PKCs reside in the cytoplasm and are
recruited to the plasma membrane only in the presence
of activators such as DAG or phorbol-esters (reviewed
in [3]). However, in the membrane-bound active state
PKC is sensitive to dephosphorylation followed by
proteolysis by endosomes or ubiquitin pathway and
therefore prolonged activation leads to decrease in
PKC protein levels (reviewed in [3]).
We have previously shown that the isophthalate
derivative HMI-1a3, which binds to the C1 domain of
A B
Fig. 3. HMI-1a3 induces senescence in PC3 and DU145 cells. (A) Representative microscopic images (209 magnification) of b-galactosidase
staining in cells exposed to vehicle (DMSO) or 4 lM HMI-1a3 for 72 h. Senescent cells with distinct morphology and blue staining are
indicated with arrows. Scale bars 200 lm. (B) beta-galactosidase activities quantified using a fluorescent substrate. Data are presented as
mean + SEM (N = 3; *P < 0.05; **P < 0.01 vs ctrl, ANOVA followed by Dunnett’s test).
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Fig. 4. Levels of p21 and E2F1 in DU145 and in PC3 prostate cancer cell lines after 24-h (DU145) or 48-h (PC3) treatment. (A,B)
Representative western blot images and quantifications from DU145 cells (A) and PC3 cells (B). Data are presented as mean + SEM (N = 3;
*P < 0.05; **P < 0.01 vs ctrl, ANOVA followed by Dunnet’s test).
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Fig. 5. Effects of PKC agonists on prostate cancer cell growth in 3D spheroid model. Representative microscopic images of live-dead-
stained spheroids of (A) LNCaP and (B) DU145 cells after 72-h exposure to 20 lM NI-15e, 4, 10, and 20 lM HMI-1a3, and 10 nM PMA as
indicated. The cells were imaged with Leica DMi8 inverted fluorescent microscope using 109 magnification. The experiments were
repeated at least three times with three replicates for each condition. Scale bars, 200 lm.
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PKCs and activates PKCs in cellular context without
inducing downregulation, inhibits the proliferation of
HeLa cells [16]. In the present study, we aimed to
characterize the effects of the isophthalate-structured
PKC modulator HMI-1a3 on prostate cancer cells
in vitro. The prostate cancer cell lines used in this
study represent different types of prostate cancer:
DU145 and PC3 cells are androgen-unresponsive cells,
whereas LNCaP cells are androgen-responsive. These
cell lines also differ from each other in relation to
PTEN and p53 expressions. DU145 express functional
PTEN, but mutated p53. PC3 cells are both PTEN
and p53 null, and LNCaP cells do not express func-
tional PTEN, but express wild-type p53 [20,26,27].
Although the role of PKC in prostate cancer has
been somewhat debated [4,5], what seems to be clear
based on various studies is that PMA-induced PKC
activation induces apoptosis in LNCaP cells [12,17–
19]. In agreement with this, we report here a strong,
PKC-dependent apoptotic response in LNCaP cells
upon treatment with HMI-1a3, which was attenuated
with the pan-PKC inhibitor G€o6983. Furthermore, the
level of caspase 3/7 activation in response to HMI-1a3
was comparable to that induced by the potent PKC
activator PMA or staurosporine, which is a widely
used inducer of apoptosis. Several mechanisms for
phorbol ester-induced apoptosis in LNCaP cells have
been suggested, including dephosphorylation of Akt,
activation of p38- and PKC-mediated secretion of
death factors (TNFa and TRAIL) [12,19]. However,
the mechanism of HMI-1a3-induced apoptosis does
not seem to involve Akt dephosphorylation. It cannot,
however, be completely ruled out, since there is a
slight trend toward Akt dephosphorylation when
LNCaP cells were treated with HMI-1a3. Whether the
secretion of death factors could explain the effect
remains to be studied.
The most problematic cases of prostate cancer are
androgen-independent and resistant to the most com-
mon prostate cancer treatment, androgen-deprivation
therapy. As in vitro models of this clinically challeng-
ing prostate cancer type we used the androgen-unre-
sponsive cell lines PC3 and DU145. PKC activation
does not induce apoptosis in these cells, but instead
treatment with HMI-1a3 drove these cells to senes-
cence. This was verified by b-galactosidase staining
and quantification of b-galactosidase activity. Further-
more, the level of p21 protein was increased and E2F1
protein level was decreased. Taken together, these
changes confirm that the cells were indeed senescent.
Although senescence has its unfavorable effects, it has
been shown that some currently used anticancer thera-
pies, such as radiation therapy or PKC activator
ingenol-3-angelate (ingenol mebutate), drive the cancer
cells to senescence and this therapy-induced senescence
is considered as one strategy for cancer therapy
[28–30]. However, it seems that the HMI-1a3-induced
senescence was not mediated by PKC, as the PKC
inhibitor G€o6983 did not block the effect of HMI-1a3
in the MTT assay. This result is in line with our previ-
ously published data in HeLa cells [16,31]. In these
cells, the effect of HMI-1a3 was not altered by phar-
macological PKC inhibition or knockdown of PKCa
or PKCd [31], but required binding to the PKC C1
domain. Other groups have previously shown that in
melanoma, breast and colon cancer cells, PKC activa-
tion induces senescence via extracellular signal regu-
lated kinase (ERK) hyperactivation [32,33]. These
studies were done using C1 domain binding diterpene
esters as PKC activators. However, some of the anti-
cancer effects of these compounds have also been
attributed to their ability to activate Ras guanine
nucleotide-releasing protein (RasGRP) [34]. Therefore,
it is plausible that the effects of HMI-1a3 in PC3 and
DU145 cells might be due to other C1 domain con-
taining proteins such as RasGRP. In our earlier stud-
ies, we were able to show that the isophthalates bind
to other DAG-responsive C1 domains, which are pre-
sent in six other protein families: chimaerins, Munc13,
myotonic dystrophy kinase-related Cdc42 binding
kinase (MRCK), protein kinase D, RasGRP, and
DAG kinase (DAGK) [31,35,36]. Unfortunately, very
little is known about these other C1 domain contain-
ing proteins in senescence.
As the isophthalate HMI-1a3 induced senescence or
apoptosis in the three prostate cancer cell lines used in
a traditional 2D cell culture system, we wanted to
investigate its effects on DU145 and LNCaP cells in a
3D cell culture model. This 3D model is considered
(patho)physiologically more relevant, since the cell–cell
contacts resemble those within a tissue better than the
plastic 2D surfaces [22]. Also, it has been shown that
cells respond to drugs in different ways in 2D and 3D
culture systems and are more sensitive to treatment in
2D models. Furthermore, the low success rates in
development of new pharmacological anticancer thera-
pies have been attributed to the use of less physiologi-
cal 2D models in drug screening [37]. In this respect,
the effect observed with HMI-1a3 in 3D cultures of
DU145 and LNCaP cells is indeed encouraging.
Although the effect was not as dramatic as with PMA,
it highlights the potential of C1 domain-targeting com-
pounds as a therapeutic strategy for cancer.
Taken together, our results indicate that PKC ago-
nists may have potential as prostate cancer drugs. This
is important for the future development of adjuvant
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therapies of castration-resistant and chemotherapy-
resistant cancers.
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